Hybrid photocurable composition

By increasing the ratio of oxetane and optimizing compositions in photocurable materials, the problem of slow curing speed of epoxy and oxetane resins under LED or LCD light sources is solved, and faster curing speed is achieved and better mechanical properties, suitable for 3D printing.

CN118901044APending Publication Date: 2024-11-05ARKEMA FRANCE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280092570.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-30
Filing Date
2022-12-15
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing photocurable materials use LED or LCD light sources, especially under longer wavelength and low intensity light, and the curing speed of epoxy and oxetane resins is slower, limiting the curing speed in 3D printing. Application performance.

Method used

By adjusting the proportion of oxetane in the composition, increasing its weight percentage to increase curing speed, and combining appropriate photoinitiators and other components, the composition is optimized to improve curing speed and mechanical properties.

Benefits of technology

Faster curing speeds at longer wavelengths and low intensity light are achieved, reaching or exceeding the performance of traditional combined systems, and improving the Green intensity and thermodynamic properties of 3D printed products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005009798070000081
    Figure BDA0005009798070000081
  • Figure BDA0005009798070000091
    Figure BDA0005009798070000091
  • Figure BDA0005009798070000092
    Figure BDA0005009798070000092
Patent Text Reader

Abstract

An actinic radiation curable composition includes one or more oxetane functional compounds; b) one or more epoxy functional compounds; c) one or more (meth) acrylate functional compounds; and d) one or more photoinitiators. The oxetane functional compound is present in the composition from 55% to 90% by weight, preferably from 60% to 90% by weight, more preferably from 70% to 90% by weight, based on the total weight of the oxetane functional compound and the epoxy functional compound in the composition.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to actinically cured materials, including those used in additive manufacturing applications. Background of the Invention

[0003] Photocurable materials are well known and used in additive manufacturing applications, also known as three-dimensional (3D) printing and including stereolithography (SL) printing processes. In recent years, as LED (light emitting diode) lamps have become less expensive and available in varying wavelengths, there has been interest in using them for the required photoirradiation to achieve curing of 3D printed parts.

[0004] Acrylate-based radiation curable systems cure rapidly, but suffer from shrinkage during curing. Hybrid systems (including blends of acrylate-based and epoxy-based and / or oxetane-based radiation curable resins) are introduced to reduce shrinkage. However, epoxy and oxetane materials cure much slower than acrylate-based systems, although they continue to cure even in the absence of light due to their cationic curing. Oxetane-based resins present even further reduced shrinkage compared to epoxy-based resins. However, known oxetane resins cure slower than epoxy-based resins when used alone.

[0005] Previously, solid-state lasers at wavelengths of 355 nm and very high intensities, such as from 25 mW (milliwatts) up to 2000 mW, and typically from 100 mW to about 1500 mW, were used to cure these epoxy, oxetane and acrylate hybrid systems. These lasers at shorter wavelengths and high intensities are sufficient to achieve rapid cure in these hybrid systems, although the cure rates of cationic-cured epoxy and oxetane resins are slower.

[0006] In recent years, LED (light emitting diode) and LCD (liquid crystal) curing systems have become popular because of their improved environmental friendliness and reduced cost compared to traditional solid-state lasers. However, LED and LCD curing systems generally provide longer wavelengths (e.g., 365nm, 385nm, 395nm, 405nm, 450nm, or 500nm) and lower intensity compared to solid-state lasers. Accordingly, epoxy and oxetane resins in these hybrid systems are cured even slower using LED or LCD-based UV curing systems. However, it is desirable to include oxetane-based resins in hybrid systems because they provide improved Green's strength and final properties compared to epoxy resins in hybrid systems including acrylates, and have the advantage of even lower shrinkage.

[0007] In a typical hybrid resin, the cationically curable portion of the composition (epoxy / oxetane) provides many advantages, but generally cures much slower than the acrylate portion of the composition. Conventionally, up to 20 wt% oxetane in combination with the epoxide, such as a 20 wt% Uvicure S130 (Sartomer / Lambson) oxetane mixture with 80 wt% Uvicure S105 (Sartomer / Lambson) epoxy (based on the weight of the cationically curable portion of the composition) is recommended to accelerate the cationic cure rate. This 20 wt% level of oxetane does improve the Green's strength to some extent, but the major portion of the Green's strength is contributed by the approximately 5 to 30 wt% high-functionality acrylate in this hybrid system. Previously, the cure speed of this composition was good enough to build the desired Green's strength in a conventional 3D printer equipped with a 355 nm solid-state laser. However, when these stereolithography (SL) resins are used in 3D printers equipped with LEDs having wavelengths of 365nm, 385nm, 395nm, or 405nm for monochrome LCD lamps, it is very difficult to build parts with sufficient Green's strength, and the slow curing of the cationic portion of the hybrid system (epoxy and oxetane) becomes a bottleneck for commercial success. This is because of the lower intensity light provided by LED and LCD 3D printers. Therefore, these hybrid systems including epoxy and oxetane resins are currently significantly limited for use in conventional hybrid system applications combined with LED or LCD printers.

[0008] Accordingly, there is a need for activated radiation-curable blends of acrylate, epoxy, and oxetane resins that provide improved cure speeds when exposed to longer wavelength and lower intensity light.

[0009] J.Appl.Polym.Sci.2020,137,48333 discloses a cationic / radical photopolymer composed of two epoxies and a tetrafunctional acrylate.

[0010] Polym. Int. 2016; 65: 1486-1492 discloses cationic photopolymerization of 3-benzyloxymethyl-3-ethyl-oxetane (MOX104) initiated by triphenylsulfonium hexafluoroantimonate under UV light.

[0011] J. Photopolym. Sct. Technol., pp. 119-124, Vol. 13, No. 1, 2000 discloses five oxetane monomers that were evaluated in a photo-cationic curing system.

[0012] J. Polym. Sci. Part A: Polym. Chem. 43: 3205-3220, 2005 discloses onium salt photoinitiated cationic ring-opening polymerization of various 3,3-di-substituted oxetane monomers.

[0013] Polymer 42 (2001) 5531-5541 discloses interpenetrating polymer networks (IPNs) synthesized by photo-induced cross-linking polymerization of a mixture of acrylate and epoxide monomers.

[0014] US 7,183,040 discloses a radiation curable composition comprising, relative to the total weight of the composition, (A) 0-29 wt% of a cationically curable component having attached aliphatic ester groups, (B) 10-85 wt% of a component containing epoxy groups, the epoxy group-containing component being different from A, (C) 1-50 wt% of a component containing oxetane groups, (D) 1-25 wt% of a multifunctional acrylate and a radical photoinitiator and a cationic photoinitiator.

[0015] US 7,696,260 discloses a composition comprising a cationically polymerizable compound, an iodonium-based cationic initiator, a sensitizer for the cationic initiator, and an antioxidant selected from phenolic antioxidants, lactone antioxidants, and combinations of these antioxidants. Adding the antioxidant to the composition helps reduce potential runaway reactions when it is exposed to actinic radiation in bulk.

[0016] US 9,861,452 discloses a liquid radiation curable resin composition for additive manufacturing, comprising from about 5 to about 30 weight percent of an oxetane; a (meth)acrylate component; a cationic photoinitiator; a free radical photoinitiator; and from about 50 to about 80 weight percent of an epoxy, further comprising a cycloaliphatic epoxy component, and an epoxy component having an aromatic glycidyl ether group, such that the majority of the epoxy is a cycloaliphatic epoxy component. Also disclosed is a process for using the liquid radiation curable resin for additive manufacturing to produce a mold for a dental brace, and a three-dimensional mold made from the liquid radiation curable resin for additive manufacturing. Summary of the invention

[0017] Various oxetane compounds were evaluated in conventional hybrid SL resins. The results showed that up to 20% by weight of oxetane (based on the total weight of the cationic curable compounds in the resin) provided some improvements in cure speed. Unexpectedly, when the proportion of the slower curing oxetane part of the cationic curable compound increased, the cure speed increased. This new discovery not only provides an effective path to accelerate the cationic cure of the hybrid system, but also allows more oxetane to be loaded in the formulation to match or exceed the printing performance of the conventional hybrid SL system, such as faster cure speed, stronger Green's strength with the desired viscosity, improved mechanical properties and better thermodynamic properties. For example, UviCure S130 mixtures up to 80% by weight with 20% by weight of cycloaliphatic epoxide (based on the total weight of the cationic curable compounds) provide maximization of the cure speed of the hybrid system. In addition, the introduction of higher weight percentages of dioxetane functional compounds into the hybrid system provides increased cure speed and meets or exceeds the target mechanical properties of the cured part.

[0018] An actinic radiation curable composition is provided. The composition comprises, consists of, or consists essentially of: a) one or more oxetane functional compounds; b) one or more epoxy functional compounds; c) one or more acrylate functional compounds; d) at least one photoinitiator; and optionally at least one additive. The composition comprises from 55 wt % to 90 wt %, preferably from 60 wt % to 90 wt %, more preferably from 70 wt % to 90 wt % of the one or more oxetane functional compounds (based on the total weight of the one or more oxetane functional compounds and the one or more epoxy functional compounds in the composition). For example, the weight ratio of the total amount of oxetane functional compounds to the total amount of epoxy functional compounds can be from 90:10 to 55:45, or from 90:10 to 60:40, or from 85:15 to 75:25.

[0019] A method for preparing a 3D printed article is also provided. The method comprises at least the following steps:

[0020] a) providing a first layer of any embodiment of the curable composition described herein onto a surface;

[0021] b) at least partially curing the first layer to provide a cured first layer;

[0022] c) providing a second layer of the curable composition onto the first cured layer;

[0023] d) at least partially curing the second layer to provide a cured second layer adhered to the cured first layer;

[0024] e) Repeating steps c) and d) a desired number of times to build a 3D printed article. DETAILED DESCRIPTION

[0025] Provided are actinic radiation curable compositions comprising, consisting of, or consisting essentially of: a) one or more oxetane functional compounds; b) one or more epoxy functional compounds; c) one or more acrylate functional compounds; d) one or more photoinitiators; and optionally at least one additive.

[0026] The actinic radiation curable composition comprises from 55 to 90 weight percent, preferably from 60 to 90 weight percent, more preferably from 70 to 90 weight percent, of one or more oxetane functional compounds, based on the total weight of the one or more oxetane functional compounds and the one or more epoxy functional compounds in the composition. If the composition comprises a mixture of oxetane functional compounds and / or a mixture of epoxy functional compounds, the above weight percentages can be calculated using the total weight of the mixture of oxetane functional compounds and / or the total weight of the mixture of epoxy functional compounds.

[0027] As shown in the examples, the inventors have discovered that, contrary to the expected result of a slower curing composition, increasing the proportion of the oxetane component (which cures the slowest of the components of the composition) shows an increased cure rate, with a peak at about 80 weight percent oxetane, based on the total weight of the oxetane and epoxy components in the composition.

[0028] a) Oxetane functional compounds

[0029] The oxetane functional compound may be a monomer and / or an oligomer. The total amount of the oxetane functional compound may be from 55 wt % to 90 wt %, preferably from 60 wt % to 90 wt %, more preferably from 70 wt % to 90 wt %, based on the total weight of the oxetane functional compound and the epoxy functional compound in the composition.

[0030] For example, the actinic radiation curable composition can include at least 55 weight percent, at least 56 weight percent, at least 57 weight percent, at least 58 weight percent, at least 59 weight percent, at least 60 weight percent, at least 61 weight percent, at least 62 weight percent, at least 63 weight percent, at least 64 weight percent, at least 65 weight percent, at least 66 weight percent, at least 67 weight percent, at least 68 weight percent, at least 69 weight percent, at least 70 weight percent, at least 71 weight percent, at least 72 weight percent, at least 73 weight percent, at least 74 weight percent, at least 75 weight percent, at least 76 weight percent, at least 77 weight percent, at least 78 weight percent, at least 79 weight percent, or at least 80 weight percent of the oxetane-functional compound, based on the total weight of the oxetane-functional compound and the epoxy-functional compound in the composition. According to other embodiments, the actinic radiation curable composition may include up to 90%, up to 89%, up to 88%, up to 87%, up to 86%, up to 85%, up to 84%, up to 83%, up to 82%, up to 81%, or up to 80% by weight of the oxetane-functional compound, based on the total weight of the oxetane-functional compound and the epoxy-functional compound in the composition. For all ranges or limits provided herein for a particular parameter, including weight percentages of a given ingredient, the invention encompasses any range extending from any lower limit to any upper limit set forth herein.

[0031] The actinic radiation curable composition may contain from 10 wt % to 90 wt %, preferably from 30 wt % to 85 wt %, more preferably from 50 wt % to 80 wt %, and most preferably from 55 wt % to 80 wt % of one or more oxetane functional compounds, based on the total weight of the curable composition. If the composition contains a mixture of oxetane functional compounds, the above weight percentages may be calculated using the weight of the mixture of oxetane functional compounds.

[0032] Suitable illustrative oxetanes include oxetanes themselves and substituted derivatives thereof, provided that the substituents do not interfere with the desired reaction / polymerization / curing of the oxetanes. The (one or more) substituents may be, for example, alkyl groups, hydroxyalkyl groups, halogens, halogenalkyl groups, aryl groups, aralkyl groups, and the like. The oxetanes may be mono-oxetanes (compounds containing a single oxetanes ring), di-oxetanes (compounds containing two oxetanes rings), tri-oxetanes (compounds containing three oxetanes rings), or oxetanes compounds containing four or more oxetanes rings. Examples of suitable oxetanes include, but are not limited to, oxetane, trimethylolpropane oxetane, 3-ethyl-3-hydroxymethyl oxetane, 1,4-bis[(3-ethyl-3-oxetanylmethoxy)methyl]benzene, 3-ethyl-3-phenoxymethyl oxetane, bis[(1-ethyl(3-oxetanyl))methyl]ether, 3,3-bis(chloromethyloxetane), 3-ethyl-3-[(phenylmethoxy)methyl]-oxetane, bis[1-ethyl(3-oxetanyl)]methylether, 1,4-bis[(3-ethyl-3-oxetanylmethoxy)methyl]benzene, 4,4-bis(3-ethyl-3-oxetanyl)methoxymethyl ]biphenyl, 3,3-bis(iodomethyl)oxetane, 3,3-bis(methoxymethyl)oxetane, 3,3-bis(phenoxymethyl)oxetane, 3-methyl-3-chloromethyloxetane, 3,3-bis(acetoxymethyl)oxetane, 3,3-bis(fluoromethyl)oxetane, 3,3-bis(bromomethyl)oxetane, 3,3-dimethyloxetane, 3,3'-[1,4-phenylenebis(methyleneoxymethylene)]bis[3-ethyloxetane], 3-ethyl-3-[[(2-ethylhexyl)oxy]methyl]oxetane, trimethylolpropane tris(3-ethyl-3-oxetanylmethyl) ether, and the like and combinations thereof.

[0033] Examples of compounds having two or more oxetane rings in the compounds useful in the present invention include: 3,7-bis(3-oxetanyl)-5-oxa-nonane, 3,3'-(1,3-(2-methylenyl)propanediylbis(oxymethylene))bis-(3-ethyloxetane), 1,4-bis[(3-ethyl-3-oxetanylmethoxy)methyl]benzene, 1,2-bis[(3-ethyl-3-oxetanylmethoxy)methyl]ethane, 1,3-bis[(3-ethyl-3-oxetanylmethoxy)methyl]propane, ethylenediamine, 1,4-bis[(3-ethyl-3-oxetanylmethoxy)methyl]benzene, 1,2-bis[(3-ethyl-3-oxetanylmethoxy)methyl]ethane, 1,3-bis[(3-ethyl-3-oxetanylmethoxy)methyl]propane, 1,4-bis[(3-ethyl-3-oxetanylmethoxy)methyl]benzene ... bis(3-ethyl-3-oxetanylmethyl)ether, dicyclopentenylbis(3-ethyl-3-oxetanylmethyl)ether, triethylene glycol bis(3-ethyl-3-oxetanylmethyl)ether, tetraethylene glycol bis(3-ethyl-3-oxetanylmethyl)ether, tricyclodecanediyl dimethylene(3-ethyl-3-oxetanylmethyl)ether, trimethylolpropane tris(3-ethyl-3-oxetanylmethyl)ether, 1,4-bis(3-ethyl-3-oxetanylmethoxy)butane, 1,6-bis(3-ethyl-3-oxetanylmethoxy)butane ) hexane, pentaerythritol tris(3-ethyl-3-oxetanyl methyl) ether, pentaerythritol tetra(3-ethyl-3-oxetanyl methyl) ether, polyethylene glycol bis(3-ethyl-3-oxetanyl methyl) ether, dipentaerythritol hexa(3-ethyl-3-oxetanyl methyl) ether, dipentaerythritol penta(3-ethyl-3-oxetanyl methyl) ether, dipentaerythritol tetra(3-ethyl-3-oxetanyl methyl) ether, caprolactone-modified dipentaerythritol hexa(3-ethyl-3-oxetanyl methyl) ether, caprolactone-modified dipentaerythritol penta(3 1-ethyl-3-oxetanyl methyl) ether, ditrimethylolpropane tetra(3-ethyl-3-oxetanyl methyl) ether, EO-modified bisphenol A bis(3-ethyl-3-oxetanyl methyl) ether, PO-modified bisphenol A bis(3-ethyl-3-oxetanyl methyl) ether, EO-modified hydrogenated bisphenol A bis(3-ethyl-3-oxetanyl methyl) ether, PO-modified hydrogenated bisphenol A bis(3-ethyl-3-oxetanyl methyl) ether, EO-modified bisphenol F (3-ethyl-3-oxetanyl methyl) ether, and the like and combinations thereof.

[0034] Additional examples of suitable oxetanes are described in the following patent documents, the disclosure of each of which is incorporated herein by reference in its entirety for all purposes: U.S. Patent Publication No. 2010 / 0222512A1, U.S. Patent No. 3,835,003, U.S. Patent No. 5,750,590, U.S. Patent No. 5,674,922, U.S. Patent No. 5,981,616, U.S. Patent No. 6,469,108, U.S. Patent No. 6,015,914, and U.S. Patent No 8377623. Suitable oxetanes are available from commercial sources, such as those sold by Toagosei Corporation under the trade names OXT-221, OXT-121, OXT-101, OXT-212, OXT-211, CHOX, OX-SC, and PNOX-1009.

[0035] Also suitable are oxetanes that also include one or more polymerizable sites of ethylenic unsaturation, such as may be supplied by a (meth)acrylate group, a (meth)acrylamide group, a vinyl group, an allyl group, or the like. 3-ethyl-3-(methacryloyloxy)methyloxetane or (3-ethyloxetane-3-yl)methyl(meth)acrylate are specific examples of such compounds. These compounds are included in the calculation of the amount of oxetanes in the curable composition.

[0036] The curable composition may also include compounds containing two or more different types of polymerizable heterocyclic rings. For example, the compound may contain one or more (one or more) oxetane rings and one or more epoxy rings (3-[(oxiranylmethoxy)methyl]oxetane is an example of such a compound). These compounds are included in the calculation of the relative amount of oxetane based on the total amount of oxetane and epoxy functional compounds in the composition as compounds containing epoxy and oxetane simultaneously.

[0037] b) Epoxy functional compounds

[0038] The epoxy-functional compound may be a monomer and / or an oligomer. The curable composition may include from 5 wt % to 40 wt %, preferably from 10 wt % to 30 wt %, more preferably from 10 wt % to 20 wt % of one or more epoxy-functional compounds, based on the total weight of the curable composition. If the composition comprises a mixture of epoxy-functional compounds, the above weight percentages may be calculated using the weight of the mixture of epoxy-functional compounds.

[0039] Exemplary epoxy functional compounds suitable for use in the present invention include mono-epoxides, bis-epoxides, and poly-epoxides (compounds containing three or more epoxide groups per molecule). Cycloaliphatic polyglycidyl compounds and cycloaliphatic polyepoxides are two classes of suitable epoxy functional compounds. Such compounds contain two or more epoxide groups per molecule and may have a cycloaliphatic ring structure containing epoxide groups as side groups (pendant to the cycloaliphatic ring) or may have a structure in which the epoxide groups are part of the cycloaliphatic ring structure.

[0040] The epoxy-functional compound may comprise, consist of or consist essentially of at least one epoxy ether. As used herein, the term "epoxy ether" refers to a compound comprising at least two epoxy groups and at least one ether bond (the ether bond is different from the cyclic ether bond in the epoxy group). In particular, the epoxy ether may comprise at least two epoxy groups and at least two ether bonds (the ether bond is different from the cyclic ether bond in the epoxy group).

[0041] The epoxy-functional compound may comprise, consist of, or consist essentially of at least one glycidyl ether. As used herein, the term "glycidyl ether" refers to a compound comprising at least two glycidyl ether groups. As used herein, the term "glycidyl ether group" refers to a group of the following formula (I):

[0042]

[0043] In one embodiment, the at least one epoxy compound may comprise, consist of, or consist essentially of at least one compound with two glycidyl ether groups (also referred to as diglycidyl ether). In another embodiment, the at least one epoxy compound a) may comprise, consist of, or consist essentially of at least one compound with three glycidyl ether groups.

[0044] The at least one epoxy a) can comprise, consist of, or consist essentially of at least one compound selected from aromatic epoxys, aliphatic epoxys, and mixtures thereof.

[0045] The epoxy a) may comprise, consist of or consist essentially of at least one aromatic epoxy. As used herein, the term "aromatic epoxy" refers to a compound comprising at least two epoxy groups connected to each other via an aromatic linker.

[0046] As used herein, the term "aromatic linker" refers to a linker comprising at least one aromatic ring, preferably at least two aromatic rings, more preferably 2 or 3 aromatic rings. Araliphatic linkers, i.e., linkers comprising both aromatic and non-aromatic moieties, are encompassed by the term aromatic linker.

[0047] The aromatic epoxy may be an aromatic glycidyl ether. As used herein, the term "aromatic glycidyl ether" refers to a compound comprising at least two glycidyl ether groups interconnected by an aromatic linker. Such a compound may be represented by the following formula (II):

[0048]

[0049] Wherein Ar is an aromatic linker;

[0050] a is at least 2, preferably 2-10, more preferably 2-6.

[0051] The aromatic glycidyl ether may be a bisphenol-based glycidyl ether. As used herein, the term "bisphenol-based glycidyl ether" refers to a compound comprising at least two glycidyl ether groups connected to each other by an aromatic linker containing a moiety derived from bisphenol. Such a compound may be represented by the above formula (II), wherein a is 2, and Ar is represented by the following formula (III):

[0052]

[0053] Where L is a linker;

[0054] R1 and R2 are independently selected from alkyl, cycloalkyl, aryl and halogen atoms;

[0055] b and c are independently 0 to 4.

[0056] In particular, L may be a linker selected from a bond, -CR3R4-, -C(=O)-, -SO-, -SO2-, -C(=CCl2)-, and -CR5R6-Ph-CR7R8-;

[0057] in

[0058] R3 and R4 are independently selected from H, alkyl, cycloalkyl, aryl, halogen alkyl and perfluoroalkyl, or R3 and R4 and the carbon atom to which they are attached may form a ring;

[0059] R5, R6, R7 and R8 are independently selected from H, alkyl, cycloalkyl, aryl, halogenalkyl and perfluoroalkyl;

[0060] Ph is a phenylene group optionally substituted with one or more groups selected from an alkyl group, a cycloalkyl group, an aryl group and a halogen atom.

[0061] More particularly, Ar may be a residue of a bisphenol without an OH group. Compounds according to formula (III), wherein Ar is a residue of a bisphenol without an OH group, may be referred to as epoxy ethers based on bisphenols, preferably glycidyl ethers based on bisphenols. Examples of suitable bisphenols are bisphenol A, bisphenol AP, bisphenol AF, bisphenol B, bisphenol BP, bisphenol C, bisphenol C2, bisphenol F, bisphenol G, bisphenol M, bisphenol S, bisphenol P, bisphenol PH, bisphenol TMC, bisphenol-Z, dinitrobisphenol A, tetrabromobisphenol A and combinations thereof.

[0062] The epoxy-functional compound may comprise, consist of, or consist essentially of at least one aliphatic epoxy. As used herein, the term "aliphatic epoxy" refers to a compound comprising at least two epoxy groups interconnected by an aliphatic linker.

[0063] As used herein, the term "aliphatic linker" refers to a linker that does not contain any aromatic rings. It may be a linear or branched, cyclic or acyclic, saturated or unsaturated hydrocarbon linker. It may be substituted, for example, by one or more groups selected from hydroxyl, halogen (Br, Cl, I, F), carbonyl, amine, carboxylic acid, -C(=O)-OR', -C(=O)-OC(=O)-R' (each R' is independently a C1-C6 alkyl). It may be interrupted by one or more bonds selected from the following: ether-(-O-), ester (-C(=O)-O- or -OC(=O)-), amide (-C(=O)-NH- or -NH-C(=O)-), urethane (-NH-C(=O)-O- or -OC(=O)-NH-), urea (-NH-C(=O)-NH-), carbonate (-OC(=O)-O-) and mixtures thereof.

[0064] The at least one aliphatic epoxy may be selected from aliphatic glycidyl ethers, epoxidized vegetable oils, and combinations thereof.

[0065] The aliphatic epoxy may be an aliphatic glycidyl ether. As used herein, the term "aliphatic glycidyl ether" refers to a compound comprising at least two glycidyl ether groups interconnected by an aliphatic linker. Such a compound may be represented by the following formula (IV):

[0066]

[0067] Wherein Al is an aliphatic linker;

[0068] d is at least 2, preferably 2-10, more preferably 2-6.

[0069] In particular, A1 may be an alkylene group optionally interrupted by one or more ether or ester bonds, or A1 may correspond to a partially or fully hydrogenated derivative of the linker of formula (III).

[0070] More particularly, Al may be a polyol P having no OH groups. OH A suitable polyol P OH Examples include ethylene glycol, 1,2- or 1,3-propylene glycol, 1,2-, 1,3- or 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,12-dodecanediol, 2-methyl-1,3-propanediol, 2,2-diethyl-1,3-propanediol, 3-methyl-1,5-pentanediol, 3,3-dimethyl-1, 5-Pentanediol, neopentyl glycol, 2,4-diethyl-1,5-pentanediol, cyclohexanediol, cyclohexane-1,4-dimethanol, norbornene dimethanol, norbornane dimethanol, tricyclodecanediol, tricyclodecane dimethanol, hydrogenated bisphenol A, B, F or S, trimethylolmethane, trimethylolethane, trimethylolpropane, di(trimethylolpropane), triethylolpropane, pentaerythritol, di(pentaerythritol), glycerol, di-, tri- or tetra-glycerol, Polyglycerol, di-, tri- or tetraethylene glycol, di-, tri- or tetrapropylene glycol, di-, tri- or tetrabutylene glycol, polyethylene glycol, polypropylene glycol, polytetramethylene glycol, poly(ethylene glycol-co-propylene glycol), sugar alcohols (i.e. erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, dulcitol, fucitol, iditol), dianhydrohexitol (i.e. isosorbide, isomannide, isoidide), hydroxylated vegetable oils, tris(2-hydroxyethyl)isocyanurate, polybutadiene polyols, polyester polyols, polyether polyols, polyorganosiloxane polyols, polycarbonate polyols, and alkoxylated (e.g. ethoxylated and / or propoxylated) derivatives thereof, as well as derivatives obtained by ring-opening polymerization of ε-caprolactone initiated by one of the above-mentioned polyols.

[0071] The aliphatic epoxy compound may be an epoxidized vegetable oil.

[0072] As used herein, the term "epoxidized vegetable oil" refers to an unsaturated vegetable oil in which at least a portion of the carbon-carbon double bonds have been converted to epoxides. Unsaturated vegetable oils typically contain one or more unsaturated diglycerides and / or triglycerides. Unsaturated diglycerides and triglycerides may correspond to diesters and triesters of glycerol and one or more fatty acids, wherein at least a portion of the fatty acids are unsaturated fatty acids. Fatty acids may be defined as monocarboxylic acids containing 4 to 32 carbon atoms, particularly 8 to 30 carbon atoms, more particularly 10 to 28 carbon atoms. Unsaturated fatty acids correspond to fatty acids containing one or more carbon-carbon double bonds. Examples of unsaturated fatty acids are myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, ricinoleic acid, elaidic acid, vaccenic acid, linoleic acid, trans-linoleic acid, alpha-linolenic acid, arachidonic acid, eicosapentaenoic acid, erucic acid, docosahexaenoic acid, and combinations thereof. Unsaturated vegetable oils can be extracted from plants or trees, for example, from seeds, fruits, flowers, bark, wood, stems or leaves of plants or trees. Examples of suitable epoxidized vegetable oils include epoxidized soybean oil, epoxidized linseed oil, epoxidized castor oil, epoxidized corn oil, epoxidized cottonseed oil, epoxidized perilla oil, epoxidized safflower oil, epoxidized palm oil, epoxidized coconut oil, epoxidized rapeseed oil, epoxidized jatropha oil, epoxidized rubber seed oil, epoxidized tung oil, epoxidized tall oil, and combinations thereof.

[0073] Also suitable are linear or branched epoxidized polyolefins, such as, for example, epoxidized polybutadiene and copolymers thereof, polyisoprene, and copolymers thereof.

[0074] Examples of compounds in which the epoxide group forms part of the alicyclic ring system include bis(2,3-epoxycyclopentyl)ether; 2,3-epoxycyclopentyl glycidyl ether, 1,2-bis(2,3-epoxycyclopentyloxy)ethane; bis(4-hydroxycyclohexyl)methane diglycidyl ether, 2,2-bis(4-hydroxycyclohexyl)propane diglycidyl ether; 3,4-epoxycyclohexylmethyl-3',4'-epoxycyclohexanecarboxylate; 3,4-epoxy-6-methyl-cyclohexylmethyl bis(3,4-epoxycyclohexylmethyl)adipate; bis(3,4-epoxy-6-methylcyclohexanemethyl)adipate; ethylene bis(3,4-epoxycyclohexane-carboxylate, ethylene glycol bis(3,4-epoxycyclohexylmethyl) ether; vinyl cyclohexene dioxide; dicyclopentadiene diepoxide; and 2-(3,4-epoxycyclohexyl-5,5-spiro-3,4-epoxy-)cyclohexane-1,3-dioxane.

[0075] Suitable illustrative mono-epoxides include glycidyl (meth)acrylate and (3,4-epoxycyclohexyl)methyl (meth)acrylate and other mono-epoxide compounds containing epoxy groups and (meth)acrylate groups.

[0076] Suitable illustrative di-epoxides include diglycidyl ethers of diols and diglycidyl esters of diacids, such as: ethylene glycol diglycidyl ether, oligo- and polyethylene glycol diglycidyl ethers, propylene glycol diglycidyl ether, oligo- and polypropylene glycol diglycidyl ethers, butanediol diglycidyl ether, alkoxylated (e.g., ethoxylated, propoxylated) butanediol diglycidyl ether, neopentyl glycol diglycidyl ether, alkoxylated (e.g., ethoxylated, propoxylated) neopentyl glycol diglycidyl ether, hexanediol diglycidyl ether, alkoxylated (e.g., ethoxylated, propoxylated) Hexanediol diglycidyl ether, cyclohexanedimethanol diglycidyl ether, alkoxylated (e.g., ethoxylated, propoxylated) cyclohexanedimethanol diglycidyl ether, hydrogenated or non-hydrogenated bisphenol A diglycidyl ether (BADGE), hydrogenated or non-hydrogenated bisphenol F diglycidyl ether (BFDGE), alkoxylated (e.g., ethoxylated, propoxylated) diglycidyl ether of bisphenols (such as bisphenol A or bisphenol F or their hydrogenated derivatives), diglycidyl esters of phthalic acid, isophthalic acid or terephthalic acid, diglycidyl esters of tetrahydrophthalic acid, and diglycidyl esters of hexahydrophthalic acid.

[0077] Suitable illustrative poly-epoxides include glycidyl ethers of compounds having three or more hydroxyl groups, such as hexane-2,4,6-triol; glycerol; 1,1,1-trimethylolpropane; ditrimethylolpropane; pentaerythritol; sorbitol; and alkoxylated (e.g., ethoxylated, propoxylated) derivatives thereof, epoxy novolac resins, and the like.

[0078] In certain embodiments, the curable composition may include one or more polymerizable, heterocyclic moiety-containing compounds that contain one or more polymerizable sites of ethylenic unsaturation in addition to one or more epoxy groups, such as may be supplied by (meth)acrylate groups, (meth)acrylamide groups, vinyl groups, allyl groups, or the like. Glycidyl methacrylate and glycidyl acrylate are specific examples of such polymerizable, heterocyclic moiety-containing compounds. In the calculation of the relative amounts of oxetanes and epoxides in the cationic curable compound in the composition, these compounds are considered epoxides. Examples of suitable epoxy (meth)acrylates include the reaction products of acrylic acid or methacrylic acid or mixtures thereof with glycidyl ethers or esters.

[0079] Other cationic curable compounds

[0080] In addition to the oxetane functional compounds and epoxy functional compounds in the hybrid composition, other cationic curable compounds can be included in the hybrid composition. Non-limiting examples of such compounds include compounds with free hydroxyl groups. The total weight of the cationic curable compounds (including epoxides, oxetanes and free hydroxyl components (such as hydroxyl groups from SpeedCure S130, OH from alcohols, polyols and OH from (meth) acrylates)) should account for 100% of the weight of the cationic system of the composition.

[0081] Even if other cationically curable compounds are present in the curable composition, the weight percentages of the one or more oxetane-functional compounds (i.e., from 55 wt % to 90 wt %, or from 60 wt % to 90 wt %, or from 70 wt % to 90 wt % of the one or more oxetane-functional compounds) mentioned herein are based on the total amount of the one or more oxetane-functional compounds and the one or more epoxy-functional compounds in the composition, not the weight of all cationically curable compounds as a whole.

[0082] Polyol can therefore be optionally included in the curable composition.As used herein, the term "polymeric polyol" refers to a polymer with two or more isocyanate-reactive hydroxyl groups per molecule.As used herein, the term "non-polymeric polyol" refers to a non-polymeric compound with two or more hydroxyl groups per molecule.In the context of the present invention, the term "polymer" refers to a compound with five or more repeating units per molecule, and the term "non-polymeric compound" refers to a compound with up to four repeating units per molecule (and therefore both monomeric compounds and oligomeric compounds contain 2 to 4 repeating units per molecule).Such as, ethylene glycol, diethylene glycol, triethylene glycol and tetraethylene glycol are all examples of non-polymeric polyols, yet the polyethylene glycol containing five or more oxyalkylene repeating units is an example of polymeric polyol.

[0083] Preferably, the hydroxyl groups are primary and / or secondary hydroxyl groups. In the case where the polyol is a polymeric polyol, according to certain embodiments, the hydroxyl groups may be located at the ends of the polymer. However, it is also possible for the hydroxyl groups to be present along the main chain of the polymer or on side chains or groups pendant from the main chain of the polymer. The polymer portion of the polymeric polyol may comprise a plurality of repeating units, such as oxyalkylene units, ester units, carbonate units, acrylic units, alkylene units or the like or combinations thereof.

[0084] According to certain embodiments of the present invention, the polymeric polyol may be represented by the following structure:

[0085] HO-R9-OH

[0086] wherein R9 is a polyether (eg, polyoxyalkylene), polycarbonate, polydiene, polyorganosiloxane, or polyester chain or linker.

[0087] Particularly preferred polymeric polyols include polyether glycols and polyester glycols. Suitable polyether glycols include, for example, polytetramethylene glycol (a hydroxy-functionalized polymer of tetrahydrofuran) and polyethylene glycol (a hydroxy-functionalized polymer of ethylene oxide). Suitable polyester glycols include, for example, poly(caprolactone), poly(lactide), poly(alkylene glycol adipate), and poly(alkylene glycol succinate).

[0088] Other types of polymeric polyols potentially useful in the present invention include polycarbonate polyols, polyorganosiloxane polyols (eg, polydimethylsiloxane diols or polyols), and polydiene polyols (eg, polybutadiene diols or polyols, including fully or partially hydrogenated polydiene polyols).

[0089] The molecular weight of polymer type polyol can be changed according to what can be needed or desired, so that in the cured composition obtained by curing curable composition, special properties are realized.For example, the number average molecular weight of polymer type polyol can be at least 300, at least 350 or at least 400g / mol.In other embodiments, polymer type polyol can have 5000g / mol or lower, 4500g / mol or lower or 4000g / mol or lower number average molecular weight.For example, polymer type polyol can have the number average molecular weight of 250 to 5000g / mol, 300 to 4500g / mol or 350 to 4000g / mol.

[0090] According to certain embodiments of the present invention, the polyol may be represented by the following structure:

[0091] HO-R9-OH

[0092] wherein R9 is a divalent non-polymeric aliphatic moiety which optionally further comprises one or more heteroatoms (such as O, N, S and / or halogen).

[0093] In certain aspects of the invention, the diol is or includes a non-polymeric polyol that is a hydrogenated dimer fatty acid (sometimes also referred to as a "dimer diol"), for example, a diol obtained by dimerizing one or more unsaturated fatty acids such as oleic acid or linoleic acid, and subsequently hydrogenating to convert the carboxylic acid groups into hydroxyl groups. 2033 (a product sold by Croda) is an example of a suitable commercially available hydrogenated dimer fatty acid.

[0094] Other types of suitable non-polymeric polyols include, but are not limited to, C2-C12 aliphatic polyols, diols, and oligomers thereof (containing up to four oxyalkylene repeating units). The aliphatic polyols or diols may be linear, branched, or cyclic in structure, wherein the hydroxyl groups are primary or secondary or one or more of each type (e.g., one primary and one secondary hydroxyl group).

[0095] Examples of suitable C2-C12 aliphatic diols include, but are not limited to, ethylene glycol, 1,2-propylene glycol, 1,3-propane diol, 1,4-butane diol, 1,6-hexane diol, diethylene glycol, 2-methyl-1,3-propane diol, 3-methyl-1,5-pentane diol, 2,2-dimethyl-1,3-propane diol, 2,2,4-trimethyl-1,5-pentane diol, and 2-methyl-2-ethyl-1,3-propane diol, and oligomers thereof containing up to four oxyalkylene repeating units.

[0096] The optional at least one polyol, if present, may be selected from ethylene glycol, propylene glycol, 1,3-propane diol, 1,2-, 1,3- or 1,4-butane diol, 2-methyl-1,3-propane diol (MPDiol), neopentyl glycol, alkoxylated derivatives of these, polyether diols, polyester diols, polycarbonate diols and combinations thereof.

[0097] The aliphatic diol (linear, branched or containing a ring structure) can be ethylene glycol, 1,2-propane diol, 1,3-propane diol, 1,4-butane diol, neopentyl glycol, 2-ethyl-1,3-hexane diol, 1,3-butane diol, 2-butyl-2-ethyl-1,3-propane diol, 2,4-diethyl-1,5-pentane diol and the like and short chain oligomers thereof (containing up to four oxyalkylene repeating units). Typically, the hydroxyl groups in such aliphatic diols are primary or secondary hydroxyl groups, which react readily with the diisocyanates used to make the inherently reactive urethane acrylate oligomers.

[0098] The polyol may be selected from ethylene glycol, propylene glycol, 1,3-propane diol, 1,2, 1,3 or 1,4 butane diol, 2-methyl-1,3-propane diol (MPDiol), neopentyl glycol, alkoxylated derivatives of these, polyether diols, polyester diols, or polysiloxane diols and combinations thereof.

[0099] The cationic curable compound may also be, for example, a cyclic ether compound, a cyclic lactone compound, a cyclic acetal compound, a cyclic thioether compound, a spiro orthoester compound, or a vinyl ether compound.

[0100] c) (Meth)acrylate functional compounds

[0101] The curable composition may contain from 5 wt % to 95 wt %, preferably from 8 wt % to 90 wt %, more preferably from 10 wt % to 80 wt % of one or more (meth)acrylate functional compounds, based on the total weight of the curable composition. If the composition comprises a mixture of (meth)acrylate functional compounds, the above weight percentages may be calculated using the weight of the mixture of (meth)acrylate functional compounds.

[0102] The curable composition may contain from 40% to 90% by weight, from 45% to 85% by weight, from 50% to 80% by weight, or from 50% to 75% by weight of the (meth)acrylate functional compound, based on the total weight of the curable composition. Alternatively, the curable composition may contain from 5% to 50% by weight, from 8% to 45% by weight, from 10% to 40% by weight, or from 10% to 30% by weight of the (meth)acrylate functional compound, based on the total weight of the curable composition. For example, the curable composition may contain at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% by weight of the (meth)acrylate functional compound, based on the total weight of the curable composition. The curable composition may contain up to 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20% by weight of the (meth)acrylate functional compound, based on the total weight of the curable composition. In an embodiment of the present invention, the composition comprises from 15 wt % to 95 wt %, preferably from 20 wt % to 90 wt %, more preferably from 20 wt % to 60 wt % of one or more (meth)acrylate functional compounds, based on the total weight of the composition.

[0103] Unlike epoxy and oxetane containing compounds, polymerizable, ethylenically unsaturated compounds suitable for use in the present invention include compounds containing at least one carbon-carbon double bond, particularly carbon-carbon double bonds that are capable of participating in a free radical reaction in which at least one carbon of the carbon-carbon double bond becomes covalently bonded to an atom, particularly a carbon atom, in a second molecule. Such a reaction can result in a polymerizable or curable compound, whereby the ethylenically unsaturated compound becomes part of a polymerized matrix or polymeric chain. In various embodiments of the present invention, the (one or more) additional ethylenically unsaturated compounds may contain one, two, three, four, five or more carbon-carbon double bonds per molecule. Combinations of various ethylenically unsaturated compounds containing different numbers of carbon-carbon double bonds may be utilized in the curable compositions of the present invention. The carbon-carbon double bond may be present as part of an α,β-unsaturated carbonyl moiety, for example an α,β-unsaturated ester moiety such as an acrylate functional group or a methacrylate functional group or an α,β-unsaturated amide moiety such as an acrylamide functional group or a methacrylamide functional group. The carbon-carbon double bond may also be present in the additional ethylenically unsaturated compound in the form of a vinyl group -CH=CH2 (such as an allyl group, -CH2-CH=CH2). Two or more different types of functional groups containing carbon-carbon double bonds may be present in the additional ethylenically unsaturated compound. For example, the ethylenically unsaturated compound may contain two or more functional groups selected from vinyl groups (including allyl groups), acrylate groups, methacrylate groups, acrylamide groups, methacrylamide groups, and combinations thereof.

[0104] Polymerizable, ethylenically unsaturated compounds that are suitable compounds for use in the present invention include the following types of compounds (wherein "functionality" refers to the number of (meth)acrylate functional groups per molecule, e.g., monofunctional = one (meth)acrylate group per molecule, difunctional = two (meth)acrylate groups per molecule):

[0105] i) cyclic monofunctional (meth)acrylate compounds such as isobornyl (meth)acrylate, cyclohexyl (meth)acrylate, 4-tert-butylcyclohexyl (meth)acrylate and alkoxylated analogs thereof;

[0106] ii) linear or branched monofunctional (meth)acrylate compounds such as isodecyl (meth)acrylate, ethoxyethoxyethyl (meth)acrylate, polyethylene mono(meth)acrylate, neopentyl glycol mono(meth)acrylate and their alkoxylated analogs, and caprolactone-based mono(meth)acrylates prepared by adding one, two, three or more moles of caprolactone to hydroxyalkyl (meth)acrylates such as hydroxyethyl (meth)acrylate ("caprolactone adducts of hydroxyalkyl (meth)acrylates");

[0107] iii) cyclic difunctional (meth)acrylate compounds such as tricyclodecanedimethanol di(meth)acrylate, cyclohexanedimethanol di(meth)acrylate and their alkoxylated analogs;

[0108] iv) linear or branched difunctional (meth)acrylate compounds such as polyethylene di(meth)acrylate, neopentyl glycol di(meth)acrylate and their alkoxylated analogs; and

[0109] v) Trifunctional (meth)acrylate compounds such as tris(2-hydroxyethyl)isocyanurate tri(meth)acrylate, trimethylolpropane tri(meth)acrylate and alkoxylated analogs thereof.

[0110] Illustrative examples of suitable polymerizable, ethylenically unsaturated compounds containing (meth)acrylate functional groups include 1,2-, 1,3- or 1,4-butanediol di(meth)acrylate, 1,6-hexanediol di(meth)acrylate, alkoxylated 1,6-hexanediol di(meth)acrylate, alkoxylated aliphatic di(meth)acrylates, alkoxylated neopentyl glycol di(meth)acrylate, cyclohexanedimethanol di(meth)acrylate, diethylene glycol di(meth)acrylate, dipropylene glycol di(meth)acrylate. Acrylates, n-alkane (meth)acrylates, polyether di(meth)acrylates, ethoxylated bisphenol A di(meth)acrylates, ethylene glycol di(meth)acrylates, 1,2- or 1,3-propylene glycol di(meth)acrylates, neopentyl glycol di(meth)acrylates, polyester di(meth)acrylates, polyethylene glycol di(meth)acrylates, polypropylene glycol di(meth)acrylates, propoxylated neopentyl glycol diacrylates, tricyclodecane dimethanol di(meth)acrylates, triethylene glycol di(meth)acrylates, tetraethylene glycol di(meth)acrylates Glycol di(meth)acrylate tripropylene glycol di(meth)acrylate, ditrimethylolpropane tetra(meth)acrylate, dipentaerythritol hexa(meth)acrylate, ethoxylated pentaerythritol tetra(meth)acrylate, dipentaerythritol penta(meth)acrylate, dipentaerythritol penta / hexa(meth)acrylate, penta(meth)acrylate, pentaerythritol tetra(meth)acrylate, ethoxylated trimethylolpropane tri(meth)acrylate, alkoxylated trimethylolpropane tri(meth)acrylate, propoxylated glyceryl tri(meth)acrylate, trimethylolpropane tri(meth)acrylate, pentaerythritol tri(meth)acrylate, propoxylated glyceryl tri(meth)acrylate, propoxylated trimethylolpropane tri(meth)acrylate, trimethylolpropane tri(meth)acrylate, tri(meth)acrylate, tri(2-hydroxyethyl)isocyanurate tri(meth)acrylate (also known as tri((meth)acryloyloxyethyl)isocyanurate), 2(2-ethoxyethoxy)ethyl (meth)acrylate, 2-phenoxyethyl (meth)acrylate, 3,3,5-Trimethylcyclohexyl (meth)acrylate, alkoxylated lauryl (meth)acrylate, alkoxylated phenol (meth)acrylate, alkoxylated tetrahydrofurfuryl (meth)acrylate, caprolactone (meth)acrylate, (meth)acryloyloxyethyl di(caprolactone), cyclic trimethylolpropane formal (meth)acrylate, cycloaliphatic acrylate compounds, dicyclopentadienyl (meth)acrylate, diethylene glycol methyl ether (meth)acrylate, ethoxylated (4) nonylphenol (meth)acrylate, ethoxylated nonylphenol (meth)acrylate, isobornyl (meth)acrylate, isodecyl (meth)acrylate, isooctyl (meth)acrylate, lauryl (meth)acrylate, methoxypolyethylene glycol (meth)acrylate, octyldecyl (meth)acrylate, stearyl (meth)acrylate, tetrahydrofurfuryl (meth)acrylate, tridecyl (meth)acrylate Esters, and / or triethylene glycol ethyl ether (meth)acrylate, tert-butyl cyclohexyl (meth)acrylate, alkyl (meth)acrylate, dicyclopentadiene di(meth)acrylate, alkoxylated nonylphenol (meth)acrylate, phenoxyethanol (meth)acrylate, octyl (meth)acrylate, decyl (meth)acrylate, dodecyl (meth)acrylate, tetradecyl (meth)acrylate, tridecyl (meth)acrylate, cetyl (meth)acrylate, hexadecyl (meth)acrylate, behenyl (meth)acrylate, diethylene glycol ethyl ether (meth)acrylate, diethylene glycol butyl ether (meth)acrylate, triethylene glycol methyl ether (meth)acrylate, 1,12-dodecanediol di(meth)acrylate, tricyclodecane methanol mono(meth)acrylate, glyceryl carbonate (meth)acrylate and combinations thereof. ,

[0111] Suitable polyether (meth) acrylates include, but are not limited to, condensation products of acrylic acid or methacrylic acid or mixtures thereof with polyether alcohols as polyether polyols. Suitable polyether alcohols may be linear or branched materials containing ether bonds and terminal hydroxyl groups. Polyether alcohols may be prepared by ring-opening polymerization of cyclic ethers such as tetrahydrofuran or alkylene oxides with a starter molecule. Suitable starter molecules include water, hydroxyl functional materials, polyester polyols and amines.

[0112] One or more carbamate diacrylates may be used in certain embodiments of the present invention. For example, the curable composition may include one or more carbamate diacrylates, and the carbamate diacrylates include difunctional aromatic carbamate acrylate oligomers, difunctional aliphatic carbamate acrylate oligomers, and combinations thereof. In certain embodiments, difunctional aromatic carbamate acrylate oligomers, such as oligomers available from Sartomer USA, LLC (Exton, Pennsylvania) under the trade name CN9782, may be used as one or more carbamate diacrylates. In other embodiments, difunctional aliphatic carbamate acrylate oligomers, such as oligomers available from Sartomer USA, LLC under the trade name CN9023, may be used as one or more carbamate diacrylates. CN9782, CN9023, CN978, CN965, CN9031, CN8881 and CN8886, all available from Sartomer USA, LLC, can all be advantageously employed as the urethane diacrylates in the compositions of the present invention.

[0113] Suitable acrylic (meth)acrylate oligomers (also sometimes referred to in the art as "acrylic oligomers") include oligomers that can be described as having an oligomeric acrylic backbone functionalized with one or more (meth)acrylate groups (which can be at the end of the oligomer or pendant to the acrylic backbone). The acrylic backbone can be a homopolymer, a random copolymer, or a block copolymer comprising repeating units of an acrylic compound. The acrylic compound can be any (meth)acrylate, such as a C1-C6 alkyl (meth)acrylate, and a functionalized (meth)acrylate, such as a (meth)acrylate with hydroxyl, carboxylic acid, and / or epoxy groups. Acrylic (meth)acrylate oligomers can be prepared using any procedure known in the art, such as oligomerizing a compound at least a portion of which is functionalized with hydroxyl, carboxylic acid and / or epoxy groups (e.g., hydroxyalkyl (meth)acrylates, (meth)acrylic acid, glycidyl (meth)acrylates) to obtain a functionalized oligomer intermediate, which is then reacted with one or more (meth)acrylate-containing reactants to introduce the desired (meth)acrylate functionality. Suitable acrylic (meth)acrylate oligomers are commercially available from Sartomer USA, LLC, such as the products identified as CN820, CN821, CN822, and CN823.

[0114] Suitable free (meth)acrylate oligomers include, for example, polyester (meth)acrylates, epoxy (meth)acrylates, polyether (meth)acrylates, polyurethane (meth)acrylates, acrylic (meth)acrylate oligomers, epoxy-functional (meth)acrylate oligomers, and combinations thereof.

[0115] According to certain embodiments, the curable composition comprises one or more polymerizable, ethylenically unsaturated compounds containing one or more hydroxyl groups per molecule. Examples of such ethylenically unsaturated compounds containing hydroxyl groups include, but are not limited to, caprolactone adducts of hydroxyalkyl (meth)acrylates (corresponding to the general formula H2C=C(R)-C(=O)-OR 1 -(OC(=O)-[(CH2)5] n OH compounds, where R = H, CH3, R 1 =C2-C4 alkylene such as ethylene, propylene, butylene, and n=1-10, for example, acryloyloxyethyl di(caprolactone)), hydroxyalkyl(meth)acrylates, alkoxylated (e.g., ethoxylated and / or propoxylated) hydroxyalkyl(meth)acrylates (including mono(meth)acrylates of ethylene glycol and propylene glycol oligomers and polymers), and the like.

[0116] The amount of polymerizable, ethylenically unsaturated, especially acrylate compounds present in the curable compositions of the present invention is not considered to be particularly critical and can be readily varied as desired, depending on parameters such as, for example, the identity or identities of the polymerizable, ethylenically unsaturated compounds(s), the nature of the other components of the curable composition, and the desired properties or attributes of the curable composition and the cured composition obtained therefrom. For example and without limitation, the curable composition may contain a total of from 5% to 90% by weight of polymerizable, ethylenically unsaturated compounds.

[0117] d) Photoinitiator

[0118] In certain embodiments of the present invention, the curable composition described herein includes one or more photoinitiators and is curable by radiant energy. A photoinitiator is a compound that changes chemically due to the action of light (or the synergy between the action of light and the electronic excitation of a sensitizing dye) to produce at least one of free radicals, acids and bases, so that the free radicals, acids and / or bases realize polymerization in one or more of the polymerizable substances present in the corresponding composition. A photoinitiator that can realize the polymerization of free radical curable components (when experiencing light of appropriate wavelength and / or intensity) is a free radical photoinitiator. A photoinitiator that can realize the polymerization of cationic curable components (when experiencing light of appropriate wavelength and / or intensity) is a cationic photoinitiator. A special photoinitiator can simultaneously act as a free radical photoinitiator and a cationic photoinitiator, although typically at least two different photoinitiators are used for this purpose.

[0119] In an embodiment, the present composition may include a free radical photoinitiator. Typically, free radical photoinitiators include those that form free radicals by either Norrish type I or P mechanisms. Such photoinitiators include those that form free radicals by cleavage (known as "Norrish type I") and those that form free radicals by hydrogen abstraction (known as "Norrish type II"). Norrish type II photoinitiators require a hydrogen donor, which acts as a source of free radicals. Since initiation is based on a bimolecular reaction, Norrish type II photoinitiators are generally slower than Norrish type I photoinitiators based on the unimolecular formation of free radicals. On the other hand, Norrish type II photoinitiators have better light absorption properties in the near-UV spectral region. The photolysis of aromatic ketones (such as benzophenone, thioxanthone, benzil and quinone) in the presence of a hydrogen donor (such as an alcohol, an amine or a thiol) results in the formation of free radicals generated by carbonyl compounds (ketyl-type free radicals) and other free radicals derived from hydrogen donors. Photopolymerization of vinyl compounds is usually initiated by free radicals generated by hydrogen donors. Kellyl radicals are usually unreactive toward vinyl compounds because of delocalization and steric hindrance of the unpaired electrons.

[0120] For example, the photoinitiator(s) may comprise at least one of α-hydroxy ketones, phenylglyoxylates, benzyl dimethyl ketals, α-amino ketones, monoacylphosphines, bisacylphosphines, phosphine oxides, and combinations thereof (such as blends of α-hydroxy ketones or acylphosphine oxides). In particular embodiments, the photoinitiator(s) may be 1-hydroxy-cyclohexyl-phenyl-ketone and / or 2-hydroxy-2-methyl-1-phenyl-1-propanone. In other embodiments, the photoinitiator(s) is or include phosphine oxides, particularly bis(2,4-6-trimethylbenzoyl)phenylphosphine oxide, (2,4,6-trimethylbenzoyl)phenylethoxyphosphine oxide, tris(2,4,6-trimethylbenzoyl)phosphine oxide, and liquid mixtures thereof.

[0121] Suitable photoinitiators include, but are not limited to, 2-methylanthraquinone, 2-ethylanthraquinone, 2-chloroanthraquinone, 2-benzylanthraquinone, 2-tert-butylanthraquinone, 1,2-benzo-9,10-anthraquinone, benzyl, benzoin, benzoin methyl ether, benzoin ethyl ether, benzoin isopropyl ether, α-methylbenzoin, α-phenylbenzoin, Michler's ketone, ketone), benzophenone, 4,4'-bis-(diethylamino)benzophenone, acetophenone, 2,2-diethyloxyacetophenone, diethoxyacetophenone, 2-isopropylthioxanthone, thioxanthone, diethylthioxanthone, 1,5-acetonaphthylene, ethyl-p-dimethylaminobenzoate, benzyl ketone, α-hydroxyketone (keto), 2,4,6-trimethylbenzoyl diphenylphosphine oxide, benzyl dimethyl ketal, benzyl ketal ( 2,2-dimethoxy-1,2-diphenylacetone), 1-hydroxycyclohexyl phenyl ketone, 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinoacetone-1,2-hydroxy-2-methyl-1-phenyl-acetone, oligomeric α-hydroxyketone, phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide, ethyl-4-dimethylaminobenzoate, ethyl(2,4,6-trimethylbenzoyl)phenylphosphonate, anisoin, anthraquinone, anthraquinone-2-sulfonic acid, sodium salt monohydrate, (Benzene) tricarbonyl chromium, benzil, benzoin isobutyl ether, benzophenone / 1-hydroxycyclohexyl phenyl ketone (50 / 50 blend), 3,3',4,4'-benzophenone tetracarboxylic acid dianhydride, 4-benzoylbiphenyl, 2-benzyl-2-(dimethylamino)-4'-morpholine butyrophenone, 4,4'-bis(diethylamino)benzophenone, 4,4'-bis(dimethylamino)benzophenone, camphorquinone, 2-chlorothiophene-9-one, dibenzocycloheptenone (dib enzosuberenone), 4,4'-dihydroxybenzophenone, 2,2-dimethoxy-2-phenylacetophenone, 4-(dimethylamino)benzophenone, 4,4'-dimethylbenzil, 2,5-dimethylbenzophenone, 3,4-dimethylbenzophenone, diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide / 2-hydroxy-2-methylpropiophenone (50 / 50 blend), 4'-ethoxyacetophenone, 2,4,6-trimethylbenzoyldiphenylphosphine oxide, phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide, ferrocene, 3'-hydroxyacetophenone, 4'-hydroxyacetophenone, 3-hydroxybenzophenone, 4-hydroxybenzophenone, 1-hydroxycyclohexylphenylketone, 2-hydroxy-2-methylpropiophenone, 2-methylbenzophenone, 3-methylbenzophenone, methylbenzoylformate, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, phenanthrenequinone, 4'-phenoxyacetophenone, (isopropyl)cyclopentadienyliron (ii) hexafluorophosphate, 9,10-diethoxy and 9,10-dibutoxyanthracene, 2-ethyl-9,10-dimethoxyanthracene, thioanthracen-9-one, and combinations thereof.

[0122] The photocurable composition of the present invention may preferably include at least one cationic photoinitiator in an amount of from about 0.2 to 10% by weight (based on the total weight of the photocurable composition). The cationic photoinitiator may be selected from those commonly used to initiate cationic photopolymerization. Examples include onium salts of anions with weak nucleophilicity, such as halogen onium salts, iodosyl salts, sulfonium salts, sulfoxonium salts or diazonium salts. Metallocene salts are also suitable as photoinitiators. Onium salts and metallocene salt photoinitiators are also suitable, as are aromatic diazonium salts, aromatic sulfonium salts, aromatic iodonium salts, metallocene-based compounds, aromatic phosphonium salts, acylsulfonium salts, and any combination thereof. In another embodiment, the cation is a polymeric sulfonium salt. In another embodiment, the cationic photoinitiator may be at least one of a triarylsulfonium salt, a diaryliodonium salt, and a metallocene-based compound, and any combination thereof. Onium salts, for example, iodonium salts and sulfonium salts and ferrocenium salts have the advantage that they are generally more thermally stable. In a particular embodiment, the cationic photoinitiator has an anion that includes at least one of the following: BF4-, AsF6-, SbF6-, PF6-[B(CF3)4]-, C6F5)4, B[C6H3-3,5(CF3)2]4-, B(C6H4CF3)4-, B(C6H3F2)4-, B[C6F4-4(CF3)]4-, Ga(C6F5)4-, [(C6F5)3B-C3H3N2-B(C 6F5)3[-,(C6F5)3B-NH2-B(C6F5)3], tetrakis(3,5-difluoro-4-alkyloxyphenyl)borate, tetrakis(2,3,5,6-tetrafluoro-4-alkyloxyphenyl)borate, perfluoroalkyl sulfonates, tris[(perfluoroalkyl)sulfonyl]methide, bis[(perfluoroalkyl)sulfonyl]imide, perfluoroalkyl phosphates, tris(perfluoroalkyl)trifluorophosphates, bis(perfluoroalkyl)tetrafluorophosphates, tris(pentafluoroethyl)trifluorophosphates, and (CH6B 11 Br6)-、(CH6B 11Br6)- or other halide carborane anions.

[0123] Examples of commercially available cationic photoinitiators include UVI-6974 and UVI-6976 (which are a mixture of S,S,S,S'-tetraphenylthiobis(4,1-phenylene)disulfonium dihexafluoroantimonate and diphenyl(4-phenylthiophenyl)sulfonium hexafluoroantimonate), UVI-6970, UVI-6960, UVI-6990 (DOW Corp.), CD1010, CD-1011, CD-1012 (Sartomer Corp.), Adekaoptomer SP150, SP-151, SP-170, SP-171 (Asahi DenkaKogyo Co., Ltd.), 261, CI-2481, CI-2624, CI-2639, CI2064 (Nippon Soda Co., Ltd.) and DTS-102, DTS-103, NAT-103, NDS-103, TPS-103, MDS-103, MPI-103, BBI-103 (Midori Chemical Co, Ltd.). Most preferred are UVI-6974, CD-1010, UVI-6976, Adekaoptomer SP-170, SP-171, CD-1012, and MPI-103 and KI78 (hexafluoroantimonium sulfonium salt from Asahi Denka). Also suitable is a mixture of S,S,S,S'-tetraphenylthiobis(4,1-phenylene)disulfonium dihexafluoroantimonate and diphenyl(4-phenylthiophenyl)sulfonium hexafluoroantimonate. The cationic photoinitiator may be used either alone or in a combination of two or more. The cationic photoinitiator may comprise - PF6 salt. Examples of known cationic photoinitiators include 4-[4-(3-chlorobenzoyl)phenylthio]phenylbis(4-fluorophenyl)sulfonium hexafluoroantimonate, 4-[4-(3-chlorobenzoyl)phenylthio]phenylbis(4-fluorophenyl)sulfonium tetrakis(pentafluorophenyl)borate, 4-[4-(3-chlorobenzoyl)phenylthio]phenylbis(4-fluorophenyl)sulfonium tetrakis(3,5-difluoro-4-methyloxyphenyl)borate, 4-[4-(3-chlorobenzoyl)phenylthio]phenylbis(4-fluorophenyl)sulfonium tetrakis(2,3,5,6-tetrafluoro-4-methyloxyphenyl)borate, tris(4-(4-acetylphenyl)thiophenyl)sulfonium tetrakis(pentafluorophenyl)borate (from BASF PAG 290), tris(4-(4-acetylphenyl)thiophenyl)sulfonium tris[(trifluoromethyl)sulfonyl]methide (from BASF GSID 26-1), tris(4-(4-acetylphenyl)thiophenyl)sulfonium hexafluorophosphate (from BASF 270) and HS-1 available from San-Apro Ltd.

[0124] Known cationic photoinitiators include, either alone or in mixtures: bis[4-diphenylsulfoniumphenyl]sulfide bishexafluoroantimonate; thiophenoxyphenylsulfonium hexafluoroantimonate (available from Chitec as Chivacure 1176), tris(4-(4-acetylphenyl)thiophenyl)sulfonium tetrakis(pentafluorophenyl)borate (available from BASF as Chivacure 1176). PAG 290), tris(4-(4-acetylphenyl)thiophenyl)sulfonium tris[(trifluoromethyl)sulfonyl]methide (from BASF GSID 26-1) and tris(4-(4-acetylphenyl)thiophenyl)sulfonium hexafluorophosphate (from BASF 270), [4-(1-methylethyl)phenyl](4-methylphenyl)iodonium tetrakis(pentafluorophenyl)borate (available from Rhodia as Rhodorsil 2074), (4-octyloxyphenyl)phenyliodonium hexafluoroantimonate (available from Hampford as OPPI FP 5386), 4-[4-(2-chlorobenzoyl)phenylthio]phenylbis(4-fluorophenyl)sulfonium hexafluoroantimonate (available from Adeka as SP-172), SP-300 from Adeka, and (PF 5386) from Hampford. 6-m (C n F 2n+1 ) m )(wherein m is an integer from 1 to 5, and n is an integer from 1 to 4) an aromatic sulfonium salt (CPI-200K or CPI-200S available from San-Apro Ltd., TK-1 available from San-Apro Ltd., or HS-1 available from San-Apro Ltd. as a monovalent sulfonium salt).

[0125] In an embodiment, the composition may include an aromatic triarylsulfonium salt cationic photoinitiator. An example of a triarylsulfonium tetrakis(pentafluorophenyl)borate cationic photoinitiator is tris(4-(4-acetylphenyl)thiophenyl)sulfonium tetrakis(pentafluorophenyl)borate. Tris(4-(4-acetylphenyl)thiophenyl)sulfonium tetrakis(pentafluorophenyl)borate is commercially available as PAG-290 is known and available from Ciba / BASF. The cationic photoinitiator may be an aromatic triarylsulfonium salt having an anion represented by: SbF6 - PF6 - 、BF4 -、(CF3CF2)3PF3 - 、(C6F5)4B - 、((CF3)2C6H3)4B - 、(C6F5)4Ga - 、((CF3)2C6H3)4Ga - Trifluoromethanesulfonate, nonafluorobutanesulfonate, methanesulfonate, butanesulfonate, benzenesulfonate, or p-toluenesulfonate. Another cationic photoinitiator is an aromatic triarylsulfonium cationic photoinitiator having an anion as a fluoroalkyl-substituted fluorophosphate. Commercially available examples of aromatic triarylsulfonium cationic photoinitiators having a fluoroalkyl-substituted fluorophosphate anion are the CPI-200 series (e.g. or ) or 300 series, which are available from San-Apro Limited.

[0126] The amount of photoinitiator is not considered critical, but may vary as may be appropriate, depending on, among other factors, the selected photoinitiator(s), the amount and type of ethylenically unsaturated compound present in the curable composition, the radiation source used, and the irradiation conditions. Typically, however, the amount of photoinitiator may be from 0.05 wt % to 5 wt %, or from about 0.2-10 wt %, based on the total weight of the curable composition.

[0127] In some embodiments of the present invention, the curable composition described herein does not include any initiator, and is curable (at least partially) with electron beam energy. In other embodiments, the curable composition described herein includes at least one free radical initiator, which decomposes when heated or in the presence of an accelerator, and is chemically curable (that is, when the curable composition is not necessarily exposed to radiation). At least one free radical initiator decomposed when heated or in the presence of an accelerator may, for example, include peroxides or azo compounds. Suitable peroxides for this purpose may include any compound, particularly any organic compound, containing at least one peroxide (-OO-) part, such as, for example, dialkyl, diaryl and aryl / alkyl peroxides, hydrogen peroxide, percarbonate, perester, peracid, acyl peroxide and the like. At least one accelerator may include, for example, at least one tertiary amine and / or one or more other reducing agents based on containing M salts (such as, for example, carboxylate salts of transition metals (such as iron, cobalt, manganese, vanadium and the like and combinations thereof). The accelerator(s) may be selected to promote the decomposition of the free radical initiator at room temperature or ambient temperature to generate active free radical species so that the curing of the curable composition is achieved without having to heat or bake the curable composition. In other embodiments, there is no accelerator and the curable composition is heated to a temperature effective to cause the decomposition of the free radical initiator and generate free radical species, which initiate the curing of the polymerizable compound(s) present in the curable composition.

[0128] Thermal initiator

[0129] In some embodiments, the curable composition described herein further includes at least one free radical initiator in addition to the photoinitiator, which decomposes when heated and thus also chemically cures the composition (that is, except that the curable composition is exposed to radiation). At least one free radical initiator may be referred to as a thermal initiator in this article. The thermal initiator that decomposes when heated or in the presence of an accelerator may, for example, include peroxides or azo compounds. Suitable peroxides for this purpose may include any compound, particularly any organic compound, which contains at least one peroxide (-OO-) part, such as, for example, dialkyl, diaryl and aryl / alkyl peroxides, hydrogen peroxide, percarbonate, perester, peracid, acyl peroxide and the like. At least one accelerator may include, for example, at least one tertiary amine and / or one or more other reducing agents based on salts containing M (such as, for example, carboxylate salts containing transition M salts (such as iron, cobalt, manganese, vanadium, etc. and the like and combinations thereof). One or more accelerators may be selected to promote the decomposition of thermal initiators at room temperature or ambient temperature to generate active free radical species, so that the curing of the curable composition is achieved without having to heat or bake the curable composition. In other embodiments, there is no accelerator and the curable composition is heated to a temperature effective to cause decomposition of the thermal initiator and generate free radical species that initiate the curing of one or more polymerizable compounds present in the curable composition. Without wishing to be bound by theory, according to some embodiments, the exotherm provided by the photoinduced polymerization provides sufficient heat to decompose such chemical (thermal) free radical initiators.

[0130] The concentration of thermal initiators in the actinic curable compositions of the present disclosure may vary as desired, depending on the particular compound(s) selected, the type(s) of polymerizable compounds(s) present in the actinic curable compositions, the curing conditions utilized, and the desired curing rate, among other possible factors. Typically, however, the actinic curable compositions may further include from 0.05 wt % to 5 wt %, preferably 0.1 wt % to 2 wt % thermal initiators, based on the total weight of the curable composition, excluding reinforcements. According to some embodiments, the typical concentration of thermal initiators may be up to about 15 wt %, based on the total weight of the curable composition, excluding reinforcements. For example, the actinic radiation curable composition may contain from 0.1 to 10 wt % thermal initiators in total, based on the total weight of the curable composition, excluding any reinforcements.

[0131] Thus, in various embodiments of the present invention, the curable compositions described herein are curable by a technique selected from radiation curing (UV radiation or electron beam curing), electron beam curing, chemical curing (using free radical initiators that decompose upon heating or in the presence of an accelerator, e.g., peroxide curing), thermal curing, or a combination thereof.

[0132] filler

[0133] The curable composition may include at least one filler, such as at least one opaque filler, which is insoluble in the other components of the photocurable composition. In particular, such fillers are insoluble in the curable composition. Further, it is preferred that at least one filler is insoluble in the solid resin matrix formed by curing the curable resin composition. The use of one or more fillers that are insoluble in the cured resin matrix allows the production of composite materials from the curable composition of the present invention.

[0134] The one or more fillers may be in any suitable shape or type. For example, the filler may be in the form of a powder, a bead, a microsphere, a particle, a granule, a screen, a fiber, or a combination thereof. If in the form of a particulate, the particle may be spherical, flat, irregular, or elongated in shape. For example, a high aspect particulate filler may be utilized. Hollow as well as solid fillers may be used in the present invention. According to various embodiments of the present invention, the filler may have an aspect ratio (i.e., the ratio of the length of a single filler element (such as a particle or fiber) to the width of a single filler element): 1:1 or higher, for example, higher than 1:1, at least 2:1, at least 3:1, at least 5:1, at least 10:1, at least 100:1, at least 1000:1; at least 10,000:1, at least 100,000:1, at least 500,000:1, at least 1,000,000:1, or even higher (i.e., effectively infinite aspect ratio). According to other embodiments, the filler may have an aspect ratio of no more than 2:1, no more than 3:1, no more than 5:1, no more than 10:1, no more than 100:1, no more than 1000:1; no more than 10,000:1, no more than 100,000:1, no more than 500,000:1 or no more than 1,000,000:1.

[0135] The surface of the filler can be modified according to any method or technique known in the art. Such surface treatment methods include, but are not limited to, sizing (e.g., coating with one or more organic substances), silanization, oxidation, functionalization, neutralization, acidification, other chemical modifications, and the like and combinations thereof.

[0136] The chemical nature of the filler can be varied and selected as desired to impart certain properties or characteristics to the product obtained when curing the photocurable composition. For example, the filler can be inorganic or organic in character. Mixed organic / inorganic fillers can also be used. Carbon-based fillers (e.g., carbon fibers, carbon black, carbon nanotubes) and mineral fillers can be used. In particularly preferred embodiments of the present invention, one or more fibrous fillers (i.e., fillers in the form of fibers) can be utilized. Suitable exemplary fibrous fillers include carbon fibers (sometimes referred to as graphite fibers), glass fibers, silicon carbide fillers, boron fibers, aluminum oxide fibers, polymeric fibers (e.g., aramid fibers), metal fibers, natural fibers (such as fibers derived from plant sources), and combinations thereof. The fibers can be of natural or synthetic origin. Any of the following types of fibers may be used: short fibers (length <10 mm), chopped fibers, long fibers (length at least 10 mm), continuous fibers, woven continuous fibers, nonwoven continuous fibers, woven fiber mats, nonwoven fiber mats (e.g., random fiber mats), biaxial mats, unidirectional mats, continuous bundles, unidirectional fibers, fiber tows, fiber fabrics, braided fibers, knitted fibers, and the like and combinations thereof. Typically, suitable fibers will have a diameter of from about 2 to about 20 microns, for example from about 5 to about 10 microns. Hollow as well as solid fibers may be used; the cross-section of the fibers may be round or irregular.

[0137] Examples of other types of fillers that can be used in the curable compositions of the present invention include clays (including organically modified clays and nanoclays), bentonites, silicates (e.g., magnesium silicate, talc, calcium silicate, wollastonite), metal oxides (e.g., zinc oxide, titanium dioxide, aluminum oxide), carbonates (e.g., calcium carbonate), micas, zeolites, talc, sulfates (e.g., calcium sulfate), and the like and combinations thereof.

[0138] In one embodiment, the curable composition comprises a relatively high loading of one or more fillers that are opaque but that are capable of scattering the rays of light to which the photocurable composition is exposed. For example, light scattering may occur where the refractive index of the filler is different from the refractive index of the portion of the curable composition that does not include the filler (before curing, which is typically a liquid containing a photocurable compound, a photoinitiator system, and possibly other non-filler additives). Such fillers may include, for example, glass fillers (e.g., glass fibers) and fillers containing transparent polymers. In such embodiments, the curable composition may include at least 20 wt%, at least 30 wt%, or at least 40 wt% of (one or more) such light scattering fillers, based on the total weight of the curable composition.

[0139] Advantageously, the curable composition of the present invention can be formulated to be solvent-free, i.e., to be free of any non-reactive volatile substances. However, in certain other embodiments of the present invention, the curable composition may contain one or more solvents, in particular one or more organic solvents, which may be non-reactive organic solvents. In various embodiments, the solvent(s) may be relatively volatile, e.g., a solvent having a boiling point of no more than 150° C. at atmospheric pressure. In other embodiments, the solvent(s) may have a boiling point of at least 40° C. at atmospheric pressure.

[0140] The one or more solvents may be selected to be able to solubilize one or more components of the curable composition and / or to adjust the viscosity or other rheological properties of the curable composition.

[0141] However, the curable compositions of the present invention may alternatively be formulated to contain little or no non-reactive solvents, e.g., less than 10% or less than 5% or even 0% non-reactive solvents, based on the total weight of the curable composition. Such less solvent or low solvent compositions may be formulated using a variety of components, including, for example, a low viscosity reactive diluent selected to make the viscosity of the curable composition sufficiently low even in the absence of solvent, so that the curing composition can be easily applied to the substrate surface at a suitable application temperature to form a relatively thin, uniform layer.

[0142] Suitable solvents may include, for example, organic solvents such as: ketones; esters; carbonates; alcohols; aromatic solvents such as xylene, benzene, toluene, and ethylbenzene; alkanes; glycol ethers; ethers; amides; and combinations thereof.

[0143] In various embodiments of the invention, the curable compositions described herein are formulated to have a viscosity of less than 10,000 cPs, or less than 9000 cPs, or less than 8000 cPs, or less than 7000 cPs, or less than 6000 cPs, or less than 5000 cPs, or less than 4000 cPs, or less than 3000 cPs, or less than 2500 cPs, or less than 2000 cPs, or less than 1500 cPs, or less than 1000 cPs or even less than 500 cPs, measured at 25° C. using a Brookfield viscometer (model DV-II) using a 27 spindle (wherein the spindle speed typically varies between 20 and 200 rpm, depending on the viscosity). In an advantageous embodiment of the invention, the viscosity of the curable composition is from 200 to 1000 cPs at 25° C.

[0144] The curable composition of the present invention may optionally contain one or more additives to replace or supplement the above-mentioned ingredients. Such additives include, but are not limited to, antioxidants, ultraviolet absorbers, light blockers, light stabilizers, foam inhibitors, flow agents or leveling agents, colorants, pigments, dispersants (wetting agents), slip additives, plasticizers, shakers, matting agents, impact modifiers, thermoplastics (such as acrylic resins, which do not contain any free radical polymerizable functional groups), waxes or other various additives, including any additives conventionally used in coatings (coating), sealants, adhesives, molding, 3D printing or ink processes.

[0145] Use of the curable composition

[0146] The curable compositions of the present invention described herein may be compositions that undergo curing by free radical polymerization or other types of polymerization (e.g., cationic polymerization). End-use applications for the curable compositions of the present invention include, but are not limited to, inks, coatings, adhesives, 3D printing resins, molding resins, sealants, composites, and the like.

[0147] According to some embodiments, curable composition can be formulated so that it is completely curable at ambient temperature or room temperature. In other embodiments, however, curable composition can be formulated so that partial curing occurs at ambient temperature or room temperature, wherein further curing is completed by heating the partially cured composition to the temperature of rising. For example, initial curing can be carried out by exposing the curable composition to a certain amount of radiation (for example, ultraviolet light), and the radiation effectively reacts the components of the curable composition containing polymerizable ethylenically unsaturated functional groups (at least partially), wherein further curing is carried out by heating the curable composition to a temperature effective for initiating the reaction of the components of the curable composition containing the polymerizable heterocyclic moiety. In such a case, it can be considered that curing involves two steps: the first curing step involves radiation (for example, light) curing and the second step involves thermal curing.

[0148] The cured compositions prepared from the curable compositions as described herein can be used, for example, in three-dimensional articles (wherein the three-dimensional article can consist essentially of or consist of the cured composition), coated articles (wherein a substrate is coated with one or more layers of the cured composition), laminated or bonded articles (wherein a first component of the article is laminated or bonded to a second component via a cured composition), composite articles, or printed articles (wherein a graphic or the like is imprinted onto a substrate (such as paper, plastic, or an M-containing substrate) using the cured composition).

[0149] The curing of the composition according to the present invention can be carried out by any suitable method, such as free radical and / or cationic polymerization. One or more initiators, such as free radical initiators (for example, photoinitiators, peroxide initiators) may be present in the curable composition. Before curing, the curable composition can be applied to the substrate surface in any known conventional manner, for example, by spraying, knife coating, roller coating, casting, barrel coating, immersion, injection, extrusion, gel deposition and the like and combinations thereof. The indirect application using a transfer process can also be utilized. The substrate can be any commercially relevant substrate, such as a high surface energy substrate or a low surface energy substrate, such as a metal substrate or a plastic substrate, respectively. The substrate can include metal, paper, cardboard, glass, thermoplastics such as polyolefins, polycarbonates, acrylonitrile butadiene styrene (ABS) and blends thereof, composites, wood, leather and combinations thereof. When used as an adhesive, the curable composition can be placed between two substrates and subsequently cured, and the cured composition thus bonds the substrates together to provide a bonded product.

[0150] Curing can be accelerated or promoted by supplying energy to the curable composition, such as by heating the curable composition and / or by exposing the curable composition to a radiation source, such as visible or UV light, infrared radiation, and / or electron beam radiation. Thus, the cured composition can be considered to be the reaction product of the curable composition formed by curing.

[0151] Multiple layers of curable compositions according to the present invention may be applied to a substrate surface; multiple layers may be cured simultaneously (eg, by exposure to a single dose of radiation) or each layer may be cured sequentially prior to application of additional layers of the curable composition.

[0152] The curable compositions of the invention described herein are particularly useful as 3D printing resin formulations, that is, compositions intended for use in the manufacture of three-dimensional articles using 3D printing technology. Such three-dimensional articles may be free-standing / self-supporting and may consist essentially of or consist of a composition according to the invention that has been cured. The three-dimensional article may also be a composite comprising at least one component consisting essentially of or consisting of the previously mentioned cured composition and at least one additional component (e.g., a metal component or a thermoplastic component) comprising one or more materials different from such a cured composition. The curable compositions of the invention may be used in digital light printing (DLP), although other types of three-dimensional (3D) printing methods may also be practiced using the curable compositions of the invention. Non-limiting examples of suitable 3D printing processes include stereolithography (SLA); digital light process (DLP); liquid crystal device (LCD); inkjet (or multi-jet) printing; continuous liquid interface production (CLIP); extrusion type processes such as continuous fiber 3D printing and cast-in-motion 3D printing; and volumetric 3D printing. The build process can be "layer by layer" or continuous. For example, liquids can be deposited in a vat, or using inkjet or gel deposition.

[0153] The method for manufacturing a three-dimensional article using the curable composition according to the present invention may comprise the following steps:

[0154] a) applying a first layer of a curable composition of any embodiment described herein in liquid form onto a surface;

[0155] b) imagewise exposing the first layer to actinic radiation to form a first exposed imaged cross-section, wherein the radiation has sufficient intensity and duration to cause at least partial curing of the first layer in the exposed area(s);

[0156] c) applying an additional layer of the curable composition in liquid form onto the previously exposed imaged cross-section;

[0157] d) imagewise exposing the additional layer to actinic radiation to form an additional imaged cross-section, wherein the radiation has sufficient intensity and duration to cause at least partial curing of the additional layer in the exposed area(s) and to cause adhesion of the additional layer to the previously exposed imaged cross-section;

[0158] e) Repeating steps c) and d) a desired number of times to build a three-dimensional article.

[0159] Although the photocuring step can be performed by any suitable method, which in some cases will depend on the components present in the curable composition, in certain embodiments of the present invention, photocuring is achieved by exposing the layer to be cured to an effective amount of radiation (e.g., electron beam radiation, UV radiation, visible light, etc.). The formed three-dimensional article can be heated to effect thermal curing.

[0160] Accordingly, in various embodiments, the present invention provides a process comprising the steps of:

[0161] a) applying a first layer of a curable composition of any embodiment described herein in liquid form onto a surface;

[0162] b) imagewise exposing the first layer to actinic radiation to form a first exposed imaged cross-section, wherein the radiation has sufficient intensity and duration to cause at least partial curing (e.g., at least 50% curing as measured by % conversion of (meth)acrylate double bonds initially present in the composition) of the layer in the exposed areas;

[0163] c) applying an additional layer of a curable composition onto the previously exposed imaged cross-section;

[0164] d) imagewise exposing the additional layer to actinic radiation to form an additional imaged cross-section, wherein the radiation is of sufficient intensity and duration to cause at least partial curing (e.g., at least 50% curing as measured by % conversion of (meth)acrylate double bonds initially present in the composition) of the additional layer in the exposed areas and to cause adhesion of the additional layer to the previously exposed imaged cross-section;

[0165] e) Repeating steps c) and d) a desired number of times to build a three-dimensional article.

[0166] The process may comprise a further step f) comprising heating the three-dimensional article to a temperature effective to thermally cure the curable composition (ie, to react the polymerizable compounds containing oxetane and epoxy moieties present in the curable composition).

[0167] In this specification, the embodiments have been described in a manner that enables writing clear and concise descriptions, but it is intended and should be understood that the embodiments can be combined or separated in various ways without departing from the present invention. For example, it should be understood that all preferred features described herein can be used in all aspects of the present invention described herein.

[0168] In some embodiments, the present invention may be interpreted herein as excluding any element or process step that does not substantially affect the basic and novel features of the curable composition or the process using the curable composition. Additionally, in some embodiments, the present invention may be interpreted as excluding any element or process step that is not specifically described herein.

[0169] Although the invention is illustrated and described herein by reference to specific embodiments, the invention is not intended to be limited to the details shown. Rather, various modifications may be made in the details within the scope and equivalents of the claims and without departing from the invention.

[0170] Example

[0171] The following materials were used in the examples, as shown in Table 1.

[0172]

[0173]

[0174]

[0175] Sample preparation procedure

[0176] Preparation of the formulations in Table 1 and Table 2:

[0177] In 125mL brown amber glass bottles, SR259, Uvicure S105 and various oxetanes were first loaded, and SpeedCure ITX, 938 and BKL were loaded in the next step. 100g mixture of each sample was sealed in a bottle by fixing the lid with white tape. Subsequently, three glass bottles were placed on a roller and continued for about 2h in a 65°C baking oven until the solution became clear. For Uvicure S150 and S160 samples, due to their high viscosity, 100g mixture was made in a 250mL metal can, by using a mechanical mixer and being heated to 45°C for about 2 hours until the solution became clear.

[0178] Using 355nm SLAViper TM A photopolymer-based additive layer manufacturing system prints a thin ribbon sample.

[0179] a. Cut PET (polyethylene terephthalate) film into squares (approximately 7.5" x 6.5") that conform to the shape of the glass (8" x 8") and attach the PET film to the glass using double-sided tape.

[0180] b. Spray the non-stick substance (Rust-o-leum Never Wet Coat 1Spray) evenly on the PET film.

[0181] c. Select the SLA Viper's Lift Motion to set the lift position to 3.3717.

[0182] d. Use a pipette to draw about 2 mL of liquid onto the glass.

[0183] e. Use the 5 μm side of the coater to apply the first layer of film.

[0184] f. Set moderate (3~5mJ / cm 2 ) Laser exposure (Ec) and penetration depth (Dp) (20-70 mils) to obtain good Green's strength of the film and start printing.

[0185] g. Once printing of the first layer is complete, use the 10 μm side of the coater to apply a second 5 μm layer of film.

[0186] h. Repeat printing and applying film until the 30 μm side is used.

[0187] i. Therefore, 6 layers (5 μm each), three 4" X 0.5" original (green) thin stretch tapes and one 35mm X 12mm DMA tape were printed per print.

[0188] j. Drain the uncured liquid resin, clean with isopropyl alcohol and air dry.

[0189] k. Carefully peel each thin strip off the PET film.

[0190] 1. Post cure the tape at 30°C for 15 minutes with 100% intensity (EnvisionTEC PCA 2000 curing unit).

[0191] m. Store the samples at 23±2°C and 50±10% relative humidity for at least 7 days before testing.

[0192] Test method:

[0193] LED-DSC Test

[0194] Photodifferential scanning calorimetry (DSC) with a custom 365 nm LED lamp setup was used for this test. All photopolymerization rate measurements were performed using a Q2000 DSC unit from TA Instruments. Lamp holders for DSC units can be customized and purchased from Arkema The resin N3D-TOUGH784 is designed to ensure an exact fit with the 365nm lamp AccucureULM-2-365 or the 405nm lamp Accucure ULM-2-405 from Digital Light Labs. The LED light is automatically triggered by connecting the "Event" outlet of the DSC unit to the Accure PhotoRheometer Ultraviolet Illumination & Measurement System. The programmable LED light exposure is turned on or off using "Event" from the Photo DSC software, but the intensity of the light can be preset from the Accure PhotoRheometer UV Illumination & Measurement System. For the measurement, approximately 5 mg of liquid sample was placed in the center of the T130522DSC Tzero pan and exposed to 50 mW / cm at a 50 mL / min N2 flow rate and 40°C. 2 Curing was performed with 365 nm or 405 nm LED light for 5 minutes, followed by a second exposure under the same conditions to determine and subtract blank. The resulting heat flow (W / g) curves were collected to analyze the maximum heat flow peak and maximum peak time.

[0195] Real-time FTIR (Fourier Transform Infrared Spectroscopy)

[0196] A real-time Fourier transform infrared (RT-FTIR) with an attenuated total reflectance (ATR) setup was used. All polymerization rate measurements were performed using a Nicolet iS50 FT-IR spectrometer from Thermo Scientific equipped with a standard DLaTGS detector. The lamp holder for the ART platform of the FTIR unit can be customized and purchased from Arkema The resin N3D-TOUGH784 is designed to print to ensure the precise fit of the 365nm lamp Accucure ULM-2-365 or 405nm lamp Accucure ULM-2-405 from Digital Light Labs. The LED lamp is manually triggered by the ultraviolet illumination and measurement system (Ultravioletillumination&Measurement System). The LED light exposure is programmable by AccuCure software. For measurement, a drop of liquid sample is placed in the center of the ATR crystal. A 3mil film is applied by a customized coating machine (3mil WFM, G1046, which comes from BYK). The LED lamp with a bracket is placed on the top of the ART platform. Then start real-time FTIR scanning to collect IR spectra. Once the liquid spectrum is collected, turn on 50mW / cm 2The intensity of the LED light source was increased to initiate the photopolymerization, which lasted for a total of 200 seconds. The COC bond was generated by the ring opening of both the epoxide and the oxetane, and the wavelength at ∼1100 cm -1 The COC IR peak height at 1727 cm-1 was also collected. -1 The peak height at 20s is calculated as the height of the C=O reference peak at 1100cm -1 / 1727cm -1 The results were used to evaluate the cationic curing speed.

[0197] Dynamic Mechanical Analyzer (DMA) Testing

[0198] DMA testing was performed with a TA Instruments DMA Q800 to determine the changes in mechanical properties in each cured DMA tape over the entire temperature range. The DMA instrument was operated from -150°C to 250°C at 3°C / min with a frequency of 1 Hz. Storage modulus (G'), loss modulus (G"), and tan(delta) curves were measured over the temperature range.

[0199] Tensile test

[0200] An Instron 5966 with a tensile test fixture with a load capacity of 10 kN was used to measure tensile properties. Thin strips were prepared for tensile properties. Six specimens were prepared for each sample, and the test speed for tensile testing was set to 5 mm / min. Tests were performed following ASTM D882-10 protocol.

[0201] Examples and performance

[0202] Table 2 tabulates the formulations, cure rates, and mechanical properties of the cured compositions in formulations including 10 wt % acrylate, based on the total weight of the composition. The components of each formulation are listed in Table 1 (amounts are shown in wt % based on the total weight of the composition). The ratio of oxetane / (oxetane+epoxy) is expressed as wt % of oxetane, based on the total weight of oxetane and epoxy.

[0203] Table 2. Various ratios of oxetane / (oxetane+epoxy) in hybrid systems

[0204]

[0205] *The higher the better; The lower the better

[0206] Table 3 tabulates the recipes, cure rates, and mechanical properties of the cured compositions in formulations including 65 wt % acrylate, based on the total weight of the composition. The components of each formulation are listed in Table 1 (amounts are shown in wt % based on the total weight of the composition). The ratio of oxetane / (oxetane+epoxy) is expressed as wt % of oxetane, based on the total weight of oxetane and epoxy.

[0207]

[0208] The results shown in Tables 2 and 3 highlight the unexpected result that when the oxetane component constitutes about 80% by weight of the total epoxy and oxetane components in the composition, the cure rate is at a maximum, as indicated by the high peak height ratio and low peak time for the composition.

[0209] Tables 4 and 5 show the difference between 20 wt% and 80 wt% oxetane, based on the total weight of epoxy and oxetane in the composition. The components of each formulation are listed in Table 1 (amounts are shown in wt% based on the total weight of the composition). The ratio of oxetane / (oxetane+epoxy) is expressed as the weight % of oxetane, based on the total weight of oxetane and epoxy.

[0210]

[0211]

[0212]

Claims

1. An actinic radiation curable composition comprising: a) one or more oxetane-functional compounds; b) one or more epoxy functional compounds; c) one or more (meth)acrylate functional compounds; d) at least one photoinitiator; wherein the composition comprises from 55 to 90 wt. %, preferably from 60 to 90 wt. %, more preferably from 70 to 90 wt. % of the one or more oxetane-functional compounds, based on the total weight of the one or more oxetane-functional compounds and the one or more epoxy-functional compounds in the composition, and wherein the composition comprises from 15 to 95 wt. % of the one or more (meth)acrylate-functional compounds, based on the total weight of the composition; and Optionally at least one additive.

2. The actinic radiation curable composition of claim 1, wherein the composition comprises from 20 to 90 weight percent, more preferably from 20 to 60 weight percent, of the one or more (meth)acrylate functional compounds, based on the total weight of the composition.

3. The actinic radiation curable composition of claim 1 or 2, wherein the composition comprises from 75 wt % to 85 wt % of the one or more oxetane functional compounds, based on the total weight of the one or more oxetane functional compounds and the one or more epoxy functional compounds in the composition.

4. The actinic radiation curable composition of any one of claims 1 to 3, wherein the one or more oxetane functional compounds comprises at least one of a monofunctional oxetane compound or a difunctional oxetane compound.

5. The actinic radiation curable composition of any one of claims 1 to 4, wherein the one or more epoxy functional compounds comprise at least one of a monofunctional epoxy compound or a difunctional epoxy compound.

6. The actinic radiation curable composition of any one of claims 1 to 5, wherein the one or more oxetane functional compounds comprises at least one of 3-ethyl-3-hydroxymethyl-oxetane, 3-ethyl-3-[(phenylmethoxy)methyl]-oxetane, bis[1-ethyl(3-oxetanyl)]methyl ether, 1,4-bis[(3-ethyl-3-oxetanylmethoxy)methyl]benzene, 4,4-bis(3-ethyl-3-oxetanyl)methoxymethyl]biphenyl, 3-ethyl-3-(methacryloyloxy)methyloxetane, trimethylolpropane tris(3-ethyl-3-oxetanylmethyl)ether, or a combination thereof.

7. The actinic radiation curable composition of any one of claims 1 to 6, wherein the one or more epoxy functional compounds comprise at least one of the following: epoxidized vegetable oils, mono-epoxides, di-epoxides, poly-epoxides, cycloaliphatic polyglycidyl compounds, cycloaliphatic polyepoxides, epoxy ethers, aromatic epoxides, aliphatic epoxides, aliphatic glycidyl ethers, linear, branched epoxidized polyolefins, or combinations thereof.

8. The actinic radiation curable composition of any one of claims 1 to 7, wherein the one or more epoxy functional compounds comprises at least one of 3,4-epoxycyclohexylmethyl 3,4-epoxycyclohexanecarboxylate, bis(3,4-epoxy-cyclohexyl)adipate, 3,4-epoxycyclohexylmethyl 3,4-epoxycyclohexanecarboxylate modified caprolactone, or a combination thereof.

9. The actinic radiation curable composition of any one of claims 1 to 8, wherein the epoxide compound and / or the oxetane compound comprises one or more (meth)acrylate functional epoxides, one or more (meth)acrylate functional oxetanes, one or more epoxy functional oxetanes, or a combination thereof.

10. The actinic radiation curable composition of any one of claims 1 to 9, wherein the composition further comprises one or more thermal initiators.

11. The actinic radiation curable composition of any one of claims 1 to 10 further comprising one or more hydroxyl functional compounds.

12. The actinic radiation curable composition of any one of claims 1 to 11 further comprising at least one filler.

13. The actinic radiation curable composition of any one of claims 1 to 12, wherein the photoinitiator comprises at least one of a cationic photoinitiator or a free radical photoinitiator.

14. A method of making a cured material, wherein the method comprises actinic radiation curing of the actinic radiation curable composition according to any one of claims 1 to 13.

15. A method for preparing a 3D printed article, comprising the following steps: a) providing a first layer of an actinic radiation curable composition according to any one of claims 1 to 13 onto a surface; b) at least partially curing the first layer to provide a cured first layer; c) providing a second layer of the actinic radiation curable composition onto the cured first layer; d) at least partially curing the second layer to provide a cured second layer adhered to the cured first layer; e) Repeating steps c) and d) a desired number of times to build a 3D printed article.

16. The method of claim 15, further comprising step f), wherein step f) comprises heating the 3D printed article to a temperature effective for thermally curing the curable composition.